Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.

doi:10.3851/IMP2475

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.

Antiviral therapy - 1 Jan 2013

Seo Sachiko, Englund Janet A, Nguyen Jack T, Pukrittayakamee Sasithon, Lindegardh Niklas, Tarning Joel, Tambyah Paul A, Renaud Christian, Went Gregory T, de Jong Menno D, Boeckh Michael J

Abstract excerpt

BACKGROUND: Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model. METHODS: We first analysed the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amantadine
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunocompromised Host

Share to Influenza A virus

Share to Influenza, Human

Share to Oseltamivir

Share to Pilot Projects

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 23264438
DOI: 10.3851/IMP2475
PMCID: PMC3912210

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.